Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 January 2015Website:
http://www.salariuspharma.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 48 min agoDividend
Analysts recommendations
Institutional Ownership
SLRX Latest News
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation.
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.
What type of business is Salarius Pharmaceuticals?
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
What sector is Salarius Pharmaceuticals in?
Salarius Pharmaceuticals is in the Healthcare sector
What industry is Salarius Pharmaceuticals in?
Salarius Pharmaceuticals is in the Biotechnology industry
What country is Salarius Pharmaceuticals from?
Salarius Pharmaceuticals is headquartered in United States
When did Salarius Pharmaceuticals go public?
Salarius Pharmaceuticals initial public offering (IPO) was on 29 January 2015
What is Salarius Pharmaceuticals website?
https://www.salariuspharma.com
Is Salarius Pharmaceuticals in the S&P 500?
No, Salarius Pharmaceuticals is not included in the S&P 500 index
Is Salarius Pharmaceuticals in the NASDAQ 100?
No, Salarius Pharmaceuticals is not included in the NASDAQ 100 index
Is Salarius Pharmaceuticals in the Dow Jones?
No, Salarius Pharmaceuticals is not included in the Dow Jones index
When was Salarius Pharmaceuticals the previous earnings report?
No data
When does Salarius Pharmaceuticals earnings report?
The next expected earnings date for Salarius Pharmaceuticals is 28 February 2025